Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Seponering af antitrombotisk behandling efter patenteret foramen ovale lukning hos unge patienter med kryptogent slagtilfælde (HALTI)

2. november 2026 opdateret af: Josep Rodes-Cabau

Seponering af antitrombotisk behandling efter patenteret Foramen Ovale lukning hos unge patienter med kryptogent slagtilfælde. HALTI-processen

To determine the safety of antithrombotic treatment discontinuation 12 months following successful transcatheter PFO closure.

Studieoversigt

Detaljeret beskrivelse

Young patients with a cryptogenic ischemic event undergoing transcatheter PFO closure exhibit a low but clinically relevant risk of bleeding (overall and major bleeding) at long-term follow-up, eventually exceeding the risk of ischemic events.

Importantly, the vast majority of major bleeding events seem to occur in patients receiving antiplatelet therapy. Preliminary data suggest that antiplatelet therapy discontinuation is not associated with any increase in ischemic events, and could potentially translate into a lower rate of major bleeding events at longer term follow-up. We therefore hypothesize that in young patients without any other comorbidities increasing the risk of stroke, shorter-term (≤1 year instead of lifelong) antiplatelet treatment could be a safe option following PFO closure.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

100

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 60 år (Voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Successful transcatheter PFO closure with any approved device
  • Patients ≤60 years diagnosed with a cryptogenic stroke/TIA who have undergone successful transcatheter PFO closure

Exclusion Criteria:

->60 year-old

  • RoPE score <6
  • Residual shunt ≥moderate following PFO closure
  • Atrial fibrillation following PFO closure
  • Presence of ≥2 cardiovascular risk factors (smoking, hypertension, dyslipidemia)
  • Diabetes mellitus
  • Thrombophilia (factor V Leiden, factor II mutation, anticardiolipin antibodies, lupus anticoagulant, anti-b2 glycoprotein-I antibodies, protein C deficiency, protein S deficiency)
  • Recurrent cerebrovascular event (stroke, TIA) within the year following PFO closure
  • Failure to provide signed informed consent
  • Absolute contraindications for an MRI study

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Antiplatelet treatment discontinuation

At 12 months post-PFO closure, patients will discontinue the antiplatelet treatment. All patients will undergo a clinical evaluation and cerebral MRI at 12 months (before antiplatelet treatment cessation) and at 24 months post-PFO closure.

All patients will undergo a clinical evaluation and cerebral MRI at 12 months (before antiplatelet treatment cessation) and at 24 months post-PFO closure.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Presence of new stroke events
Tidsramme: 12 months

1)Acute episode of a focal or global neurological deficit with at least one of the following: change in level of consciousness, hemiplegia, hemiparesis, numbness or sensory loss affecting one side of the body, dysphasia or aphasia, hemianopia, amaurosis fugax or other new neurological symptom(s) consistent with stroke.(2)Duration of a focal or global neurological deficit ≥ 24 hours OR < 24 hours if available neuroimaging documents a new hemorrhage or infarct; OR the neurological deficit results in death.

12 months
Presence of new ischemic lesions
Tidsramme: 24-month follow-up

Evaluated by MRI

24-month follow-up

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of new cerebral ischemic lesions
Tidsramme: 24-month follow-up

Evaluated by MRI

24-month follow-up
Volume of new cerebral ischemic lesions
Tidsramme: 24-month follow-up

Evaluated by MRI

24-month follow-up
Number of ischemic events
Tidsramme: 24-month follow-up

Stroke, TIA

24-month follow-up
Number of ischemic events
Tidsramme: 3-year follow-up

Stroke, TIA

3-year follow-up
Number of ischemic events
Tidsramme: 4-year follow-up

Stroke, TIA

4-year follow-up
Number of ischemic events
Tidsramme: 5-year follow-up

Stroke, TIA

5-year follow-up
Number of ischemic events
Tidsramme: 6-year follow-up

Stroke, TIA

6-year follow-up
Number of ischemic events
Tidsramme: 7-year follow-up

Stroke, TIA

7-year follow-up
Number of ischemic events
Tidsramme: 8-year follow-up

Stroke, TIA

8-year follow-up
Number of ischemic events
Tidsramme: 9-year follow-up

Stroke, TIA

9-year follow-up
Number of ischemic events
Tidsramme: 10-year follow-up

Stroke, TIA

10-year follow-up
Rate of bleeding
Tidsramme: 24-month follow-up

Life-threatening, major or minor bleeding

24-month follow-up
Rate of bleeding
Tidsramme: 3-year follow-up

Life-threatening, major or minor bleeding

3-year follow-up
Rate of bleeding
Tidsramme: 4-year follow-up

Life-threatening, major or minor bleeding

4-year follow-up
Rate of bleeding
Tidsramme: 5-year follow-up

Life-threatening, major or minor bleeding

5-year follow-up
Rate of bleeding
Tidsramme: 6-year follow-up

Life-threatening, major or minor bleeding

6-year follow-up
Rate of bleeding
Tidsramme: 7-year follow-up

Life-threatening, major or minor bleeding

7-year follow-up
Rate of bleeding
Tidsramme: 8-year follow-up

Life-threatening, major or minor bleeding

8-year follow-up
Rate of bleeding
Tidsramme: 9-year follow-up

Life-threatening, major or minor bleeding

9-year follow-up
Rate of bleeding
Tidsramme: 10-year follow-up

Life-threatening, major or minor bleeding

10-year follow-up

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

8. juli 2020

Primær færdiggørelse (Anslået)

1. juni 2027

Studieafslutning (Anslået)

1. august 2032

Datoer for studieregistrering

Først indsendt

14. juli 2020

Først indsendt, der opfyldte QC-kriterier

14. juli 2020

Først opslået (Faktiske)

17. juli 2020

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

4. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. november 2026

Sidst verificeret

1. november 2026

Mere information

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner